World's Top 50 Companies in gastrointestinal drugs in 2025 Watch List: Statistics Report (2024–2035)

Description

According to a research report published by Spherical Insights & Consulting, The Global Gastrointestinal Drugs Market Size is projected to Grow from USD 54.19 Billion in 2024 to USD 91.1 Billion by 2035, at a CAGR of 5.33 % during the forecast period 2025–2035. The gastrointestinal drugs market offers future opportunities in personalized medicine, biologics development, microbiome-targeted therapies, expanded OTC product lines, and rising demand from aging populations and emerging markets with increasing digestive health awareness.

 

Introduction                                                              

The gastrointestinal (GI) drugs market refers to the industry focused on the development, production, and distribution of medications used to treat disorders of the digestive system, including acid reflux, ulcers, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and constipation. Key driving factors fueling market growth include the increasing prevalence of gastrointestinal disorders, rising geriatric population, growing awareness of digestive health, and advancements in drug formulations such as biologics and targeted therapies. Additionally, lifestyle changes, poor dietary habits, and stress-related conditions are contributing to higher demand for effective GI treatments worldwide.

 

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the gastrointestinal drugs market.

 

Gastrointestinal Drugs Market Size & Statistics

• The Market Size for Gastrointestinal Drugs was Estimated to be Worth USD 54.19 Billion in 2024.
• The Market Size is going to Expand at a CAGR of 5.33 % between 2025 and 2035.
• The Global gastrointestinal drugs Market Size is Anticipated to Reach USD 91.1 Billion by 2035.
• Asia Pacific is Expected to generate the highest demand during the forecast period in the gastrointestinal drugs market.
• Middle East & Africa is Expected to Grow the fastest during the forecast period in the gastrointestinal drugs market.

 

Regional growth and demand                                      

Middle East & Africa is expected to grow the fastest during the forecast period in the gastrointestinal drugs market. This rapid growth is driven by improving healthcare infrastructure, increasing government healthcare spending, a rising burden of gastrointestinal disorders, and greater access to medicines. Additionally, growing awareness of digestive health, expanding urban populations, and the entry of international pharmaceutical companies into emerging African and Middle Eastern markets are contributing to the region’s accelerating demand for gastrointestinal treatments.

 

Asia Pacific is expected to generate the highest demand during the forecast period in the gastrointestinal drugs market. Asia-Pacific is expected to generate the highest demand in the gastrointestinal drugs market during the forecast period. This growth is primarily driven by the region’s large and aging population, particularly in countries such as China, India, and Japan, where age-related gastrointestinal issues are becoming more prevalent. Additionally, rapid urbanization and lifestyle changes have led to a rise in digestive disorders, increasing the need for effective treatment options. Improved access to healthcare services, expanding pharmaceutical infrastructure, and growing awareness about gastrointestinal health are further contributing to market growth. Moreover, global pharmaceutical companies are increasing their investments in the region, focusing on local R&D, clinical trials, and distribution networks, which is expected to accelerate the availability and adoption of advanced GI treatments.

 

Top 5 Gastrointestinal Drug Startups Impacting the Pharma Sector

1. OrphoMed – Small Molecules

Gastrointestinal (GI) conditions, including irritable bowel syndrome (IBS), constipation, gastric ulcers, and hemorrhoids, impact millions worldwide. Small molecules are now becoming appealing options for treating these diseases. Small molecules facilitate oral consumption and intestinal drug delivery for convenience and enhanced effectiveness, respectively. OrphoMed is a startup located in the US that creates dimer therapeutics derived from small molecules. The startup employs a unique platform technology to produce conformationally stable dimers that exhibit the receptor pharmacology of the original molecule. This approach allows enhancements in the effectiveness and safety of small-molecule medications. The startup's portfolio features medications for IBS and cystic fibrosis, along with a liver-friendly pain reliever.

 

2. Enthera – Selective Inhibitors

Nonsteroidal anti-inflammatory medications (NSAIDs) frequently negatively impact the gut's mucous lining, resulting in gastric erosion due to extended use. Selective inhibitors aim at particular metabolic pathways responsible for GI disorders to restore the disease condition. These medications also exhibit comparable effectiveness to NSAIDs but lack their adverse effects. Enthera, an Italian startup, provides biologics for autoimmune diseases. Their approach revolves around a mechanism that includes the insulin-like growth factor binding protein 3 (IGFBP3) and manages stem cell apoptosis in the intestines, pancreas, and various other tissues. Enthera's pipeline features a selective inhibitor that reduces autoimmune responses in Type 1 diabetes and IBS.

 

3. Edesa Biotech – Secretory Phospholipases A2 (sPLA2) Inhibitors

sPLA2 are enzymes recognized for triggering various inflammatory diseases by converting phospholipids into arachidonic acid. Consequently, sPLA2 inhibitors address inflammation at its origin instead of responding after inflammation has manifested. As their application doesn't result in significant side effects or treatment halts, startups are investigating their potential for addressing various GI disorders. Edesa Biotech is a Canadian company focused on creating therapies for anorectal and skin disorders. The startup's approach blocks sPLA2 to stop the inflammatory process at its onset. EB02, the top candidate in their pipeline, is being studied for the treatment of hemorrhoids. The startup is additionally developing an inhibitor medication for anal fissures.

 

4. Scioto Biosciences – Bacterial Therapeutics

In recent years, extensive research has confirmed the importance of the gut microbiome in various gastrointestinal disorders. Additionally, numerous gastrointestinal diseases are associated with alterations in the gut microbiome's composition. Introducing specific beneficial bacteria might be able to restore the disease condition. In pursuit of this goal, startups are investigating microbiome therapies for treating gastrointestinal issues. Scioto Biosciences is a startup located in the US that offers microbiome-based therapies. It creates the Activated Bacterial Therapeutics (ABT) platform that enables the administration of live therapeutic bacteria to the intestines. The approach employs microparticles and a prebiotic component to guarantee the survival of bacteria in the gut as a biofilm. The primary candidate of the startup is being examined for addressing gut dysbiosis in preterm infants, obesity in children, and C. difficile infections.

 

5. BiomX – Phage Therapy

Another method to affect the gut microbiome is to use viruses to eliminate harmful bacteria. Phage therapy involves utilizing bacteriophages to address bacterial infections. In contrast to antibiotics, phages target only one or a limited number of bacterial strains with high specificity. This allows pharmaceutical startups to create treatments for targeted actions in the gastrointestinal tract. Israeli company BiomX creates tailored phage treatments for conditions like IBD and cancer. The approach employs phage discovery and cutting-edge synthetic biology, alongside multi-dimensional optimization to create a tailored phage mixture. BX003, an experimental phage therapy in progress, addresses primary sclerosing cholangitis, an uncommon liver disease linked to IBD.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the gastrointestinal drugs market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.

 

Top 11 Companies Leading the Gastrointestinal Drugs Market

1. Takeda Pharmaceuticals
2. Allergan Plc
3. Novo Nordisk A/S
4. AstraZeneca Plc
5. AbbVie Inc.
6. Valeant Pharmaceuticals Inc.
7. Johnson & Johnson
8. Bayer AG
9. Boehringer Ingelheim GmbH
10. GlaxoSmithKline Plc.
11. Janssen Biotech Inc.

 

1. Takeda Pharmaceuticals

Headquarters: Tokyo, Japan

Takeda Pharmaceuticals is Japan’s largest pharmaceutical company and a global leader in the biopharmaceutical industry. Founded in 1781, Takeda focuses on core therapeutic areas including gastroenterology, oncology, neuroscience, and rare diseases. It has a strong research and development pipeline, particularly in innovative biologics and vaccines. Following its acquisition of Shire plc in 2019, Takeda significantly expanded its presence in rare diseases and plasma-derived therapies. The company operates in over 80 countries and is committed to delivering life-transforming treatments and sustainable healthcare solutions through science and innovation.

 

2. Allergan Plc

Headquarters: Dublin, Ireland (prior to acquisition by AbbVie)

Allergan Plc was a global pharmaceutical company known for its expertise in eye care, neurosciences, medical aesthetics, and gastroenterology. Headquartered in Dublin, Ireland, it became widely recognized for products like Botox, Restasis, and Linzess. Allergan built a robust pipeline through innovation and strategic acquisitions. In 2020, the company was acquired by AbbVie Inc., strengthening AbbVie’s product portfolio in aesthetics and specialty care. Although it now operates under AbbVie, Allergan’s brand and key products remain prominent in global markets, continuing to contribute significantly to AbbVie’s diversified pharmaceutical business.

 

3. Novo Nordisk A/S

Headquarters: Bagsværd, Denmark

Novo Nordisk A/S is a leading global healthcare company specializing in diabetes care, obesity management, and rare blood and endocrine disorders. Headquartered in Bagsværd, Denmark, the company was founded in 1923 and is best known for its innovative insulin therapies and GLP-1 receptor agonists such as Ozempic and Wegovy. Novo Nordisk also focuses on chronic disease prevention and treatment through a strong R&D pipeline and global manufacturing network. With a presence in over 80 countries, it is committed to improving patient outcomes through research-driven, sustainable healthcare solutions.

 

4. AstraZeneca Plc

Headquarters: Cambridge, United Kingdom

AstraZeneca Plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters in Cambridge, UK. Established in 1999 through the merger of Astra AB and Zeneca Group, the company focuses on oncology, cardiovascular, respiratory, immunology, and rare diseases. AstraZeneca gained global recognition for developing one of the early COVID-19 vaccines in collaboration with Oxford University. Its strategic investments in biologics and precision medicine have positioned it as a key player in life sciences innovation. The company has a global presence and continues to invest in cutting-edge research and development.

 

5. AbbVie Inc.

Headquarters: North Chicago, Illinois, USA

AbbVie Inc. is a global biopharmaceutical company headquartered in North Chicago, Illinois. Formed in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on innovative treatments in immunology, oncology, neuroscience, and eye care. Its flagship product, Humira, has been one of the world’s top-selling drugs for autoimmune diseases. The company expanded its portfolio through strategic acquisitions, including the 2020 acquisition of Allergan Plc. AbbVie is known for its strong R&D capabilities and commitment to improving patients' lives through advanced biologics and targeted therapies across more than 70 countries worldwide.

 

Are you ready to discover more about the gastrointestinal Drugs market?

The report provides an in-depth analysis of the leading companies operating in the global gastrointestinal drugs market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Takeda Pharmaceuticals.
   • Business Overview
   • Company Snapshot
   • Products Overview
   • Company Market Share Analysis
   • Company Coverage Portfolio
   • Financial Analysis
   • Recent Developments
   • Merger and Acquisitions
   • SWOT Analysis
2. Allergan Plc
3. Novo Nordisk A/S
4. AstraZeneca Plc
5. AbbVie Inc.
6. Valeant Pharmaceuticals Inc.
7. Johnson & Johnson
8. Bayer AG
9. Boehringer Ingelheim GmbH
10. GlaxoSmithKline Plc.
11. Janssen Biotech Inc.

 

Conclusion

The gastrointestinal drugs market is poised for steady growth, driven by the rising prevalence of digestive disorders, aging global populations, and growing awareness of gastrointestinal health. Technological advancements in drug formulation, microbiome research, and biologics are transforming treatment approaches. Regions like Asia Pacific and the Middle East & Africa are expected to play crucial roles in shaping demand and innovation due to expanding healthcare infrastructure and population health needs. With increasing R&D investments and strategic collaborations among pharmaceutical leaders and emerging startups, the market presents vast opportunities for companies seeking to provide effective, patient-centered GI treatments in the years ahead.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter